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Abstract
Objectives To review the technique, indications, results
and working mechanisms of sacral neuromodulation
(SNM) for lower urinary tract dysfunction.
Methods The available literature on SNM for lower uri-
nary tract dysfunction was searched. Based on the infor-
mation available in the literature and also based on
personal experience, the urological indications, technique,
mechanisms of action and results of SNM are presented
and discussed.
Results SNM for lower urinary tract dysfunction involves
stimulation of the 3rd sacral nerve with an electrode
implanted in the sacral foramen and connected to a pulse
generator. The technique is accepted by the FDA since
1997. Currently, SNM for lower urinary tract dysfunction
has been successfully used in about 26,000 patients with
various forms of lower urinary tract dysfunction, including
urgency, frequency and urgency incontinence as well as
non-obstructive urinary retention. The actual procedure of
SNM consists of a minimal invasive technique and is
effective in about 70% of the patients who have been
implanted with a permanent system. Also, in pelvic pain,
interesting results have been described. SNM modulates
the micturition reflexes at different levels in the central
nervous system.
Conclusions Sacral neuromodulation is a safe and effec-
tive therapy for various forms of lower urinary tract dys-
function, including urgency, frequency and urgency
incontinence as well as non-obstructive urinary retention. It
should be the first choice after failure of maximal conser-
vative therapy.
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Introduction
Chronic types of lower urinary tract dysfunction (urgency,
frequency, urgency incontinence as well as non-obstructive
urinary retention) still present a therapeutic challenge.
Most patients are initially treated with conservative thera-
pies (bladder retraining, pelvic floor exercises, biofeedback
and intermittent catheterization) often supported with
pharmacological therapy. However, a significant propor-
tion of patients do not achieve an acceptable level of
therapeutic benefit. Several surgical procedures (bladder
transsection, transvesical phenol injection, augmentation
cystoplasty and urinary diversion) have been advocated
with variable efficacy and significant morbidity. Sacral
neuromodulation (SNM) offers an alternative treatment for
these patients [1]. SNM was developed in the early 1980 s
by Tanagho and Schmidt. They demonstrated that contin-
uous stimulation of the sacral root S3 with an electrode
connected to an implanted pulse generator (Fig. 1) could
modulate detrusor and sphincter activity and stabilize
micturition reflexes [2].
S3 sacral neuromodulation received approval by the US
Food and Drug Administration (FDA) for the treatment of
urge incontinence in 1997 and for urgency/frequency and
non-obstructive urinary retention in 1999 [3]. Currently,
SNM for lower urinary tract dysfunction has been suc-
cessfully used in about 26,000 patients.
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Indications
Sacral neuromodulation is a potential treatment for patients
with various forms of bladder dysfunction. Although SNM
currently only has FDA approval for overactive bladder
and urinary retention, clinical benefit has been observed for
various other chronic pelvic floor disorders, including
faecal incontinence, chronic pelvic pain and interstitial
cystitis.
Overactive bladder
Overactive bladder (OAB) syndrome involves a group of
symptoms including urgency and frequency with or with-
out urgency incontinence (OAB wet and OAB dry). Before
considering treatment, a proper clinical evaluation should
be performed in order to rule out underlying causes, such as
infections, malignancies and anatomical abnormalities.
Conservative management is always advocated as an initial
intervention. However, often, these conservative treatments
do not result in sufficient symptom relief, and many
patients cannot tolerate the side effects of drugs. When
conservative treatments fail after 8–12 weeks, alternative
therapies can be considered [4]. At present, several mini-
mally invasive techniques are available including SNM,
posterior tibial nerve stimulation (PTNS) and intravesical
injections with botulinum toxin (BTX). PTNS can be seen
as an alternative option to SNM but needs to be repeated
at regular intervals in order to have persistent results.
No comparative trial between PTNS and SNM is available
yet. BTX is currently not approved by the FDA for the
indication OAB, but the initial results are promising. The
most common adverse events are high post-void resid-
ual requiring clean intermittent self-catheterization, and
urinary tract infection. BTX treatment also needs to be
repeated at regular intervals. At this moment, there are no
comparative trials between BTX and SNM available, and
hence, the decision to offer SNM or BTX will be the result
of an informed consent between the doctor and the patient.
Scheepens et al. identified several predictive factors in
SNM in a retrospective study evaluating 211 patients [5].
They found that a history of intervertebral disc prolapse
surgery and the duration of complaints are factors that may
affect the chance of a successful test stimulation. Everaert
et al. reported that patients with a history of surgery for
stress incontinence had a significantly better long-term
outcome with SNM, whatever their symptoms were [6].
In a group of 100 patients undergoing test stimulation,
Koldewijn et al. did not show any predictors of success,
although it appeared that patients with detrusor overactivity
and urethral instability responded best to SNM [7].
Amundsen et al. demonstrated that age greater than 55
was associated with a lower response to SNM [8]. For the
time being, a trial stimulation remains the only reliable
factor in predicting success with permanent treatment.
Urinary retention
Voiding can be impaired by either bladder outlet obstruc-
tion or insufficient contractility of the detrusor. In turn,
bladder outlet obstruction can be of anatomical or func-
tional origin. Anatomical obstruction is often caused by
prostate enlargement, urinary tract tumours, bladder neck
stenosis or urethral stricture. Although poorly understood,
functional aetiologies include detrusor external sphincter
dyssynergia or detrusor bladder neck dyssynergia. In
addition, pelvic floor dysfunction can cause inhibition of
detrusor function, resulting in difficult bladder emptying
and varying degrees of urinary retention. Fowler et al.
described overactivity of the urethral sphincter as a cause
of urinary retention, especially in young women (Fowler’s
syndrome) [9].
Also, neurological disorders (e.g., spinal cord disease,
spinal disc hernation, multiple sclerosis, small fibre neu-
ropathy) should be considered as a possible basis for non-
obstructive urinary retention. Patients with ‘idiopathic’
urinary retention often have a history of a triggering event
such as pelvic surgery or even emotional stress. They also
frequently have a history of dysfunctional disorders in their
childhood, such as lifelong constipation or urinary tract
infections [10].
Previously, there was no effective treatment for func-
tional urinary retention except clean intermittent self-
catheterization. More invasive treatments, such as urethral
dilatation and bladder neck incisions, have been associated
with inconsistent results, a high relapse rate and compli-
cations. SNM has been recognized as an effective treatment
Fig. 1 Stimulation of the S3 nerve root with an electrode in the sacral
foramen and connected to an implanted stimulator
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for patients with functional urinary retention. A large
multicentre clinical trial in 1999 resulted in FDA approval
of SNM for treating idiopathic non-obstructive chronic
urinary retention and now has become a well-established
treatment modality for patients with non-obstructive uri-
nary retention [3, 11]. No predictors of success have cur-
rently been identified. It is important to note that an
elevated cystometric capacity or absence of detrusor con-
tractility does not predict failure of SNM. However,
Bertapelle et al. demonstrated that patients who showed a lack
of detrusor response to acute stimulation of the sacral nerve
roots might have a lower chance of treatment success [12].
Patients with pelvic floor hypertonicity, such as in Fowler’s
syndrome, appear to have a higher success rate [13].
Pelvic pain
Although SNM is not an FDA-approved treatment for
patients with urological pain syndromes, various authors
have reported on the ‘off-label’ treatment and the results
seem promising with a success rate of 72–77% [14, 15].
Mechanism of action
Although the exact mechanism of SNM is not well
understood, it seems to involve modulation of the spinal
cord reflexes and brain networks by peripheral afferents,
rather than direct stimulation of the motor response of the
detrusor or urethral sphincter. In patients with overactive
bladder, SNM is thought to inhibit detrusor activity without
affecting urethral resistance or the strength of detrusor
contractions during voiding [16]. The observation that
early, bilateral SNM initiated during spinal shock could
prevent the development of detrusor overactivity in com-
plete spinal cord injury might indicate modulation at the
level of the spinal cord itself [17]. PET studies indicated
that at the level of the brain, the activity of centres involved
in activation or inhibition of the micturition reflex can be
enhanced or reduced with SNM [18]. This results in acti-
vation or inhibition of lower urinary tract activity. Blok
et al. compared the effect of acute and chronic SNM on
brain activity by evaluating the regional cerebral blood
flow with PET [19]. Their findings suggested that acute
SNM predominantly modulates areas involved in sensori-
motor learning, whereas chronic SNM influences areas
related to awareness of bladder filling, the urge to void and
the timing of micturition.
For urinary retention, SNM has been postulated to
suppress the guarding reflex, resulting in decreased urethral
sphincter tone and thereby facilitating voiding. Animal
studies indicated that the guarding reflexes can be modu-
lated by afferent nerve activation and inhibit bladder
activity by spinal or supraspinal pathways [20]. In contrast,
the results of a study of 30 women with Fowler’s syndrome
showed that the maximum urethral closure pressure did not
change significantly. Instead, the return of voiding ability
seemed to be attributable to a slight increase in detrusor
contractility [21]. In a recent study, functional MRI was
used to evaluate brain responses to bladder filling in
patients with Fowler’s syndrome [22]. The data showed
abnormal brain responses in these patients, which are most
likely caused by abnormally strong inhibition of the blad-
der afferents by overactivity of the urethral sphincter. The
authors suggested that SNM acts at a sacral level, by
blocking the urethral inhibition of afferent information
from the bladder. Because the transmission of afferent
information to the brain is restored, bladder sensations
return as well as the ability to void.
Technique of sacral neuromodulation
For SNM, one of the sacral nerves (usually S3) is stimu-
lated with a quadripolar lead (Model 3889, Medtronic Inc.),
which is positioned in the sacral foramen. The lead is
connected to an implantable, reprogrammable pulse gen-
erator (Interstim I or II, Medtronic Inc.) The pulse gener-
ator can be implanted by creating a subcutaneous pocket in
the lower abdomen or buttock. Patients are selected for
SNM treatment based on their response to test stimulation
with a temporary electrode. During the test procedure, a
needle is inserted into the third sacral foramen. Next, it is
connected to an external stimulator, and current is applied.
Correct placement is confirmed by evaluating the sensory
and motor responses to stimulation. Typical responses are
sensation in the anal, vaginal or perineal area, contraction
of the levator ani muscle, and flexion of the great toe on the
ipsilateral side of stimulation. In addition, correct position
of the needle can be confirmed by fluoroscopy. When
adequate responses have been obtained, the electrode is
inserted through the needle, and the needle is removed. In
turn, the electrode is connected to an external stimulator.
During the trial stimulation, which lasts for a minimum of
3 days, the response to subchronic stimulation can be
evaluated.
Initially, test stimulation was performed with the per-
cutaneous nerve evaluation (PNE), in which a basic wire
electrode is connected to an external stimulator. However,
due to the high risk of lead migration, the test duration is
rather limited, and the reported success rate is between 40
and 50% [3]. Later, the two-stage implantation procedure
was introduced, which enables screening with the perma-
nent electrode during the first stage [23]. If the patient is
considered eligible for definitive SNM, the implantable
neurostimulator (INS) is inserted in a second stage. This
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procedure enables prolonged screening for up to 1 month,
resulting in a success rate of approximately 80%, which is
significantly higher than with PNE testing [23]. Before the
introduction of the tined lead, the permanent lead was
implanted under direct vision and in turn secured to the
sacral periosteum during an open surgical technique. Spi-
nelli et al. introduced a self-anchoring ‘tined’ lead in 2002,
allowing percutaneous placement of the lead under radio-
logical guidance (Fig. 2) [24]. Potential advantages of the
tined lead include a shorter operation time, reduced risk of
infection, less pain and shorter post-operative recovery
time. In addition, the lead can be inserted under local
anaesthesia, enabling evaluation of the sensory responses
to acute stimulation.
Clinical results
If more than 50% improvement in voiding symptoms is
observed based on the comparison of the results of the
voiding diary that is kept before and during the test stim-
ulation, patients are considered eligible candidates for
SNM treatment. Depending on the type of complaint,
different primary voiding parameters are used to evaluate
the clinical effect. In patients with OAB wet, improvement
in incontinence parameters is considered most important
(number of leakages per day and the number of pads per
day). In patients with OAB dry, the voiding frequency and
voided volume per void are evaluated, and in patients with
chronic urinary retention, reduction in the volume per
catheterization and increase in voided volume are assessed.
Numerous reports on the clinical efficacy of SNM have
been published. In early studies by Tanagho et al. SNM
resulted in restoration of continence in patients with
detrusor overactivity due to suprasacral spinal cord injury
[2]. In 1995, Bosch et al. evaluated 18 implanted patients
with urgency incontinence [25]. The voiding diaries of
these patients showed a highly significant drop in leakage
episodes and frequency, with a significant increase in the
average voided volume. The number of pads used per day
dropped significantly as well. The effect was durable, as 13
patients who were followed for more than 2 years main-
tained the same initial improvement. In addition, early
studies reported on the use of SNM for the restoration of
voiding in patients with non-obstructive urinary retention.
Gajewski et al. reported long-lasting improvement in 70%
Fig. 2 Percutaneous technique of lead implantation. After correct
positioning of the patient, a test needle is used to probe and localize
the third sacral foramen. Next, the test lead is inserted near the nerve
through the needle and connected to an external stimulator. Due to
silicone barbs (‘tines’), the lead is self-anchored in the sacral foramen
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of the implanted patients [26]. Jonas et al. also reported a
high success rate in these patients [11].
Long-term outcome of SNM for lower urinary tract
dysfunction has been assessed in several clinical trials.
Table 1 presents an overview of a number of studies that
evaluated the long-term efficacy. All studies showed that
SNM treatment is safe and effective for patients with OAB
as well as patients with urinary retention, and most studies
showed a higher success rate in the retention group. The
largest prospective study, including 17 centres worldwide,
reported a long-term success rate of approximately 70%
[3, 6].
Follow-up and adverse events
Directly after implantation, the implantable neurostimula-
tor (INS) is activated, and optimal stimulation settings are
chosen by evaluating the sensory response to different
combinations. The tip of the implanted lead contains 4
stimulation points, and each one can be used as a cathode
or anode. Also, the case of the stimulator can be used as an
anode, which results in unipolar type of stimulation. When
the lead itself is used for both the cathode and anode,
bipolar stimulation is the result. The stimulation setting
(uni- or bipolar) that gives the best sensory response (anal,
vaginal or perineal) at the lowest amplitude is considered
optimal. The amplitude of stimulation is normally set just
above sensory threshold. Not much is known about the
optimal pulse rate with chronic stimulation. Although it is
generally advised to set the pulse rate between 10 and
16 Hz, the effect of different pulse rates on treatment
efficacy have never been evaluated in clinical studies. This
also applies for the pulse width, which is advised to set at
210 ms. Patients receive a ‘patient programmer’, which
they can use to turn the INS on or off when necessary.
Also, the programmer grants the ability to make small
alterations in the stimulation amplitude. Patients are
advised to keep the INS on during the day and night.
Patient follow-up after implantation of the neurostimu-
lator is scheduled after 6 weeks, 6 months and yearly
thereafter. During each follow-up visit, the stimulation
parameters are checked in order to evaluate patient
compliance and correct use of the patient programmer.
Also, the impedance can be measured. If the impedance is
less than 50 Ohms or more than 4,000 Ohms, there may be
a short cut or an open circuit as a result of damage to the
lead. In case of decreased efficacy without signs of lead
damage, parameter settings can be adjusted. In case of
permanent loss of efficacy, an X-ray will be considered to
rule out lead migration. If all these changes do not lead to
any improvement and all parameters and sensory responses
are correct, it is often challenging to find a satisfactory
solution. First of all, the symptoms of the patients have to
be re-evaluated to rule out other causes of therapy failure
(e.g., stress incontinence, neurological disease), especially
in patients who have been treated with SNM for several
years. Next, replacement of the lead or contralateral
placement of a new lead can be considered. Eventually,
bilateral stimulation could be attempted.
Pain can occur in 24–34% with long-term follow-up and
can be located at the site of the INS or at the site where the
stimulation sensation is perceived. This can often be dif-
ferentiated by turning the stimulator off. If pain symptoms
persist, they are often a result of mechanical discomfort of
the INS. If pain symptoms decrease, they are often stim-
ulation-related. The physician can attempt to relieve pain
symptoms by altering the stimulation settings. If no pain
relief occurs, repositioning of the INS or lead can be
necessary.
Conclusions
Sacral neuromodulation is well-established treatment
option for patients with lower urinary tract dysfunction.
The exact mechanism of action most likely involves a
combination of different modes of action, involving the
neuroaxis at different levels. The efficacy has been proven
in several clinical trials, with reported 5-year efficacy of
approximately 70%. Due to technological advancements,
the technique has become minimally invasive and is easy to
apply even on an out-patient basis.
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Table 1 Long-term results of
SNM treatment
Success of treatment was
defined as the percentage of
patients who had a successful
outcome at last follow-up visit
(more than 50% improvement in
key voiding diary variables)






Siegel et al. [27] 2000 112 62 26
Bosch et al. [28] 2000 45 60 47
Dasgupta et al. [29] 2004 26 77 37
van Kerrebroeck et al. [3] 2007 105 70 49
Sutherland et al. [30] 2007 104 69 22
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